Kineta Total Liabilities 2014-2024 | KANT
Kineta total liabilities from 2014 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Kineta Annual Total Liabilities
(Millions of US $) |
| 2023 |
$7 |
| 2022 |
$13 |
| 2021 |
$25 |
| 2020 |
$59 |
| 2019 |
$20 |
| 2018 |
$22 |
| 2017 |
$10 |
| 2016 |
$10 |
| 2015 |
$15 |
| 2014 |
$20 |
| 2013 |
$5 |
Kineta Quarterly Total Liabilities
(Millions of US $) |
| 2024-06-30 |
$9 |
| 2024-03-31 |
$9 |
| 2023-12-31 |
$7 |
| 2023-09-30 |
$8 |
| 2023-06-30 |
$10 |
| 2023-03-31 |
$13 |
| 2022-12-31 |
$13 |
| 2022-09-30 |
$4 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$20 |
| 2021-12-31 |
$25 |
| 2021-09-30 |
$37 |
| 2021-06-30 |
$40 |
| 2021-03-31 |
$43 |
| 2020-12-31 |
$59 |
| 2020-09-30 |
$17 |
| 2020-06-30 |
$19 |
| 2020-03-31 |
$20 |
| 2019-12-31 |
$20 |
| 2019-09-30 |
$24 |
| 2019-06-30 |
$24 |
| 2019-03-31 |
$23 |
| 2018-12-31 |
$22 |
| 2018-09-30 |
$25 |
| 2018-06-30 |
$23 |
| 2018-03-31 |
$22 |
| 2017-12-31 |
$10 |
| 2017-09-30 |
$22 |
| 2017-06-30 |
$11 |
| 2017-03-31 |
$8 |
| 2016-12-31 |
$10 |
| 2016-09-30 |
$14 |
| 2016-06-30 |
$14 |
| 2016-03-31 |
$12 |
| 2015-12-31 |
$15 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$20 |
| 2013-12-31 |
$5 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
